Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Non-Current Debt for 10 consecutive years, with $339.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 189.09% to $339.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $339.9 million, a 189.09% increase, with the full-year FY2025 number at $339.9 million, up 189.09% from a year prior.
  • Non-Current Debt was $339.9 million for Q4 2025 at Madrigal Pharmaceuticals, roughly flat from $339.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $339.9 million in Q4 2025 to a low of $48.7 million in Q2 2022.
  • A 4-year average of $129.6 million and a median of $116.1 million in 2024 define the central range for Non-Current Debt.
  • Biggest YoY gain for Non-Current Debt was 190.17% in 2025; the steepest drop was 1.52% in 2025.
  • Madrigal Pharmaceuticals' Non-Current Debt stood at $49.3 million in 2022, then surged by 134.29% to $115.5 million in 2023, then increased by 1.81% to $117.6 million in 2024, then soared by 189.09% to $339.9 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Non-Current Debt are $339.9 million (Q4 2025), $339.8 million (Q3 2025), and $118.4 million (Q2 2025).